Odaily Noon News
1. Polymarket's cumulative fee revenue has exceeded $11.2 million, and it is expected to cover the total LP subsidy expenditure this month;
2. The top 100 addresses on Hyperliquid contributed more than 80% of the trading volume;
3. Powell: If investigated, I will not leave after my term as chairman ends;
4. Trump on tariffs: I have the absolute right to impose tariffs in another form, and I have already started doing so;
5. Trump considers seizing Iran's Kharg Island oil hub;
6. Ledger executive: If the US bans stablecoin yields, other countries may fill the gap;
7. Lisk Head of Research: In the US, Germany, Brazil and other countries, the actual holdings of USDC have surpassed USDT;
8. Due to copyright disputes, ByteDance has suspended the global release plan for Seedance 2.0;
9. 10x Research: On-chain capital flows and position changes may drive bitcoin's next round of price volatility;
10. Base and Solana account for 97% of AI agent-to-agent trading share;
11. A white-hat hacker claims to have discovered a serious vulnerability in Injective, involving over $500 million in on-chain assets, but only received a $50,000 bounty;
12. The address that received funds from Tornado Cash is suspected to be the attacker in the CAKE/THE liquidation event on Venus, profiting about $5.07 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
